
1. General Information
- Brand: WEGOVY
- Active ingredient: Semaglutide
- Strength: 1.7 mg
- Dosage form: Injection
- Route: Subcutaneous injection
- Drug class: GLP-1 receptor agonist
- Administration: Once weekly
- Prescription status: Prescription medicine
- Manufacturer/brand owner: Novo Nordisk
The 1.7 mg injection is one of the available Wegovy dose strengths. It may be used as a maintenance dose in appropriate patients depending on treatment response and tolerability.
2. Product Information
WEGOVY FlexTouch contains semaglutide, which mimics the action of the naturally occurring hormone GLP-1. The medicine is supplied as a prefilled injection pen designed for subcutaneous administration.
The current U.S. prescribing information lists 1.7 mg/0.75 mL among the available Wegovy injection strengths.
3. Uses of WEGOVY 1.7 mg Injection
WEGOVY injection may be prescribed:
- For long-term weight reduction and maintenance in adults with obesity.
- For adults who are overweight and have at least one weight-related medical condition.
- For eligible adolescents aged 12 years and older with obesity.
- To reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity.
- Alongside a reduced-calorie diet and increased physical activity.
The exact indication and availability may differ by country, so treatment should follow the local prescribing information.
4. Benefits of This Medicine
When prescribed appropriately, potential benefits include:
- Supports long-term weight management.
- Helps reduce appetite and calorie intake.
- Can support clinically meaningful weight reduction when combined with diet and physical activity.
- Helps maintain weight reduction with continued treatment.
- In eligible adults with established cardiovascular disease and overweight/obesity, it can reduce the risk of major cardiovascular events such as cardiovascular death, non-fatal heart attack, or non-fatal stroke.
Individual results vary, and Wegovy should not be considered a substitute for a healthy diet, physical activity, or appropriate medical care.
5. Side Effects of WEGOVY 1.7 mg
Possible adverse effects include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dizziness
- Indigestion
- Abdominal distension
- Burping
- Flatulence
- Gastroesophageal reflux
- Hair loss
More serious adverse reactions can include pancreatitis, gallbladder disease, kidney problems related to dehydration, serious gastrointestinal reactions, allergic reactions, and hypoglycemia, particularly when used with certain diabetes medicines.
6. Common Side Effects
The most frequently reported side effects include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dyspepsia
- Dizziness
- Abdominal bloating/distension
Gastrointestinal effects can be more noticeable when the dose is increased and may improve as the body adjusts.
7. How to Use WEGOVY FlexTouch 1.7 mg
WEGOVY injection is administered once weekly, on the same day each week, at any time of day, with or without food. It is injected under the skin of the abdomen, thigh, or upper arm.
Important points:
- Use it exactly as prescribed by your healthcare professional.
- Do not change the dose without medical advice.
- The 1.7 mg dose is generally reached through gradual dose escalation rather than being used as the initial dose.
- Follow the instructions supplied with the specific FlexTouch pen available in your country.
- Do not share a Wegovy pen with another person.
8. How WEGOVY Works
Semaglutide acts similarly to GLP-1, a hormone involved in appetite regulation and blood-glucose control.
It works partly by acting on areas of the brain involved in appetite, helping reduce hunger and calorie intake. It also delays gastric emptying, which can contribute to increased feelings of fullness.
This combination can help patients consume fewer calories and support weight reduction when used with diet and physical activity.
9. Safety Advice
Important: WEGOVY is a prescription medicine and should be used under medical supervision.
- Do not use Wegovy if you or a family member has had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Do not use it if you have had a serious allergic reaction to semaglutide or its ingredients.
- Tell your doctor if you have pancreatic, kidney, gallbladder, or diabetic-retinopathy problems.
- Tell your healthcare provider about all medicines you take.
- Wegovy should not be combined with other semaglutide-containing medicines or other GLP-1 receptor agonists unless specifically directed by a healthcare professional.
- Inform your healthcare provider before surgery or procedures involving anesthesia or deep sedation.
- Wegovy may cause fetal harm; patients planning pregnancy should discuss treatment with their healthcare provider. For weight-management indications, the U.S. prescribing information recommends discontinuing Wegovy at least 2 months before a planned pregnancy.
- Store the pen according to the product's official storage instructions. The manufacturer's current pen guidance states refrigeration at 2°C–8°C; specific storage instructions can vary by product presentation and local labeling.
- Seek urgent medical attention for severe abdominal pain, symptoms of a serious allergic reaction, or other severe/unusual symptoms.
10. FAQs
Q1. What is WEGOVY 1.7 mg Injection?
WEGOVY 1.7 mg is a semaglutide-containing prescription injection used for specified weight-management and cardiovascular-risk-reduction indications.
Q2. How often is WEGOVY 1.7 mg taken?
It is administered once weekly.
Q3. Is 1.7 mg the starting dose?
No. Wegovy injection is normally started at a lower dose and gradually increased. The U.S. prescribing information describes escalation every four weeks; 1.7 mg may be selected as a maintenance dose in appropriate patients.
Q4. Can WEGOVY be used with other semaglutide medicines?
Concomitant use with other semaglutide-containing products or other GLP-1 receptor agonists is not recommended.
Q5. Can WEGOVY replace diet and exercise?
No. It is intended to be used together with a reduced-calorie diet and increased physical activity.
Q6. Where is WEGOVY injected?
It is injected subcutaneously into the abdomen, thigh, or upper arm.
Q7. Can everyone use WEGOVY?
No. Certain medical conditions, medications, pregnancy considerations, and allergy history may make it unsuitable. A healthcare professional should determine whether it is appropriate.
Q8. What should I do if I experience severe side effects?
Contact a healthcare professional promptly. Severe abdominal pain, difficulty breathing, swelling, or other potentially serious symptoms require urgent medical assessment.
11. Substitutes for WEGOVY 1.7 mg
There is no universal substitute that is appropriate for every patient. Depending on the indication, medical history, availability, and local approval, a healthcare professional may consider other prescription weight-management treatments.
Potential alternatives may include medicines containing:
- Semaglutide — another semaglutide product may be considered only when medically appropriate; products are not automatically interchangeable.
- Tirzepatide — a different incretin-based prescription medicine used for certain weight-management indications.
- Other approved anti-obesity medicines, depending on the patient's circumstances and the country.
Patients should not switch between Wegovy and another GLP-1/incretin medicine on their own. A healthcare professional should determine the appropriate alternative, dose, and transition plan.
12. SEO Keywords
Primary Keywords:
- WEGOVY FlexTouch 1.7 mg Injection
- WEGOVY 1.7 mg Injection
- Semaglutide 1.7 mg Injection
- WEGOVY semaglutide injection
- WEGOVY 1.7 mg pen
- Semaglutide injection exporter
- WEGOVY medicine exporter India
- WEGOVY 1.7 mg exporter from India
- Pharmaceutical exporter from Nagpur India
- Genuine WEGOVY 1.7 mg supplier India
Long-Tail B2B Keywords:
- WEGOVY FlexTouch 1.7 mg Injection exporter from India
- WEGOVY 1.7 mg semaglutide injection supplier from India
- WEGOVY 1.7 mg pharmaceutical exporter from Nagpur India
- Semaglutide 1.7 mg injection wholesale supplier India
- WEGOVY 1.7 mg injection international pharmaceutical supplier
- WEGOVY 1.7 mg medicine exporter to USA
- WEGOVY 1.7 mg medicine exporter to UK
- WEGOVY 1.7 mg medicine exporter to Australia
- WEGOVY 1.7 mg medicine exporter to Singapore
- WEGOVY 1.7 mg medicine exporter to Canada
- WEGOVY 1.7 mg medicine exporter to South Korea
- WEGOVY 1.7 mg medicine exporter to UAE
- Semaglutide injection pharmaceutical supplier from India
- Genuine semaglutide 1.7 mg injection supplier
- WEGOVY FlexTouch pharmaceutical export supplier
Keywords







